Royal Bank of Canada’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-798,569
| Closed | -$144M | – | 7327 |
|
|
2017
Q3 | $144M | Buy |
798,569
+43,500
| +6% | +$6.06M | 0.07% | 247 |
|
|
2017
Q2 | $78.3M | Sell |
755,069
-162,749
| -18% | -$13.3M | 0.04% | 372 |
|
|
2017
Q1 | $72M | Buy |
917,818
+188,778
| +26% | +$11.7M | 0.04% | 374 |
|
|
2016
Q4 | $32.7M | Buy |
729,040
+82,649
| +13% | +$4.05M | 0.02% | 741 |
|
|
2016
Q3 | $36.1M | Buy |
646,391
+479,185
| +287% | +$26.7M | 0.02% | 653 |
|
|
2016
Q2 | $8.36M | Sell |
167,206
-21,691
| -11% | -$1.07M | 0.01% | 1572 |
|
|
2016
Q1 | $8.67M | Buy |
188,897
+1,491
| +0.8% | +$72.2K | 0.01% | 1475 |
|
|
2015
Q4 | $11.5M | Buy |
187,406
+178,717
| +2,057% | +$12.6M | 0.01% | 1339 |
|
|
2015
Q3 | $484K | Sell |
8,689
-5,811
| -40% | -$366K | ﹤0.01% | 3546 |
|
|
2015
Q2 | $884K | Buy |
14,500
+8,675
| +149% | +$495K | ﹤0.01% | 3037 |
|
|
2015
Q1 | $336K | Sell |
5,825
-9,166
| -61% | -$614K | ﹤0.01% | 3835 |
|
|
2014
Q4 | $864K | Sell |
14,991
-13,809
| -48% | -$581K | ﹤0.01% | 3057 |
|
|
2014
Q3 | $821K | Buy |
+28,800
| New | +$713K | ﹤0.01% | 3007 |
|
Royal Bank of Canada's KITE Position: Q4 2017 in Review
Royal Bank of Canada sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 798,569 shares — an estimated $144M sold.
Royal Bank of Canada first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $144M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Royal Bank of Canada reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Royal Bank of Canada sold 798,569 Kite Pharma, Inc. shares in Q4 2017, an estimated $144M.
- Royal Bank of Canada first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- Royal Bank of Canada's Kite Pharma, Inc. position peaked at $144M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Royal Bank of Canada's 13F filing for Q4 2017, filed 14 Feb 2018.